Current status of antimicrobial resistance in Indian healthcare system: combating antimicrobial resistance with precision medicine · Shinde A, Mohan A, Bulusu VM et al.

Conclusion and future prospective

This narrative review provides an overview of the AMR status in Indian healthcare settings, with an emphasis on outpatient settings. We explore the impact of AMR on clinical outcomes and review the current efforts and interventions such as AMR Stewardship programs. In addition, we comprehensively discussed precision medicine, pharmacogenomics and other Omics based approaches aimed at curbing AMR. This study highlights the growing issue of antimicrobial resistance (AMR), particularly from multidrug-resistant (MDR) Gram-negative bacteria, which presents serious difficulties for healthcare systems. MDR in common pathogens like E. coli, Klebsiella pneumoniae, and Staphylococcus aureus is well-documented, but specific resistance mechanisms remain underexplored. AMR studies often reflect data from selected regions in India or isolated hospitals. A research gap exists in understanding how resistance patterns vary across rural vs. urban settings and in primary, secondary, and tertiary healthcare levels.

Few studies assess the direct impact of AMR on treatment outcomes, length of hospital stay, and mortality rates. Poor sanitation, inappropriate antibiotic usage in agriculture, and a lack of healthcare infrastructure in rural regions are examples of environmental variables that contribute to the spread of AMR, which are poorly understood. Research focusing on the clinical effects of drug-resistant infections in vulnerable populations, particularly in Indian settings, utilizes pharmacogenomics methods to provide personalized treatments through genetic profiling and therapeutic drug monitoring. Additionally, studies on the effectiveness of antimicrobial stewardship initiatives and community-based ASPs aim to reduce antimicrobial resistance. Our knowledge of the elements contributing to resistance in developing nations such as India would be improved further by research integrating environmental and socioeconomic factors with AMR patterns.

The emergence of multidrug-resistant organisms (MDROs) raises morbidity and death rates which complicates treatment regimens and raises healthcare expenses from a clinical standpoint (Nathwani et al., 2014; Kadam et al., 2024). Treatment of infections caused by resistant pathogens, including extensively carbapenem-resistant Enterobacterales (CRE), and methicillin-resistant Staphylococcus aureus (MRSA), is difficult because only few effective antibiotics are available. When pan-resistant strains appear, it is then especially concerning and highlights the seriousness of the issue because for that there are now no viable antibiotics.

Using antibiotics carelessly in aquaculture and agriculture has made the issue worse. The widespread use of antibiotics for both infection treatment and livestock growth promotion lead to the selection of resistant strains that can spread to humans through the food chain and environmental pathways (Page and Gautier, 2012). The necessity of a “One Health” approach that acknowledges the interdependence of environmental, animal, and human health is highlighted (Jani et al., 2021). Antimicrobial stewardship programs (ASPs) are essential for reducing AMR. Targeted therapy, which lessens the need for broad-spectrum antibiotics and the selection pressure for resistant bacteria, can be made possible by quick and precise diagnostic methods. In the same way, ASPs urge for careful consumption of antibiotics, supporting de-escalation techniques, suitable dosage, and treatment length to curb antimicrobial resistance.

The pharmaceutical pathway for novel antibiotics is still limited due to scientific, regulatory and financial obstacles. Developing new antibiotics requires modest commercial returns, significant time, investment and commitment. By promoting research in novel anti-infective therapy, we can revive the antimicrobial pipeline for which we would need development through public private collaborations, market entry incentives, simplified regulatory processes and international cooperation which is essential to effectively address AMR. International frameworks like World Health Organization (WHO) have goals on Global Action Plan (GAP) on AMR which are, are stronger surveillance, better infection prevention and control and easier access to high-quality antimicrobials. However, there have been major obstacles such as antimicrobial access and healthcare infrastructure of some nations.

A successful response towards curbing AMR requires addressing these inconsistencies through technology transfer, capacity building and fair access to diagnostics and antimicrobials. Precision medicine helps to make customized and informed medical decisions, tailoring therapies by considering patient’s genetic makeup, immune response, specific infection, and socio-environmental and lifestyle factors. By using precision medicine’s patient-centric approach we can closely monitor drug levels using therapeutic drug monitoring (TDM) (Roberts et al., 2012). This helps maintain the peak therapeutic efficacy of drugs while mitigating adverse effects and drug-related toxicities. In conclusion, we need more research focusing on the clinical consequences of drug-resistant infections in vulnerable populations especially in Indian Outpatient settings which could be achieved using pharmacogenomics methods to provide personalized treatments using genetic profiling and TDM.